Becton, Dickinson and Company (BDX) Q1 2025 earnings summary

Executive summary

• Announced intent to separate Biosciences and Diagnostic Solutions business, targeting completion in fiscal 2026, to create two focused, high-growth entities and unlock value for both New BD and the separated business.

• Q1 FY25 delivered strong results: revenue reached $5.2 billion, up 9.8% as reported, 9.6% currency-neutral, and 3.9% organic year-over-year, driven by volume growth, pricing, and acquisitions.

• Adjusted diluted EPS rose 28% to $3.43, with GAAP diluted EPS at $1.04, and net income of $303 million.

• Returned over $1 billion to shareholders in Q1 via dividends and a $750 million accelerated share buyback.

• Affirmed full-year currency-neutral and organic revenue growth guidance; raised midpoint of adjusted EPS guidance despite FX headwinds.

Financial highlights

• Q1 revenue grew 9.8% year-over-year to $5.2 billion, led by Medical segment growth and the acquisition of Advanced Patient Monitoring.

• Adjusted gross margin expanded 370 bps to 54.8%; adjusted operating margin up 340 bps to 23.6%.

• Free cash flow was ~$600 million, in line with expectations, impacted by timing of one-time payments.

• Cash and short-term investments at quarter-end were $728 million; net leverage at 2.9x.

• Effective income tax rate dropped to 0.9% from 21.6%, mainly due to a partial release of a non-U.S. tax credit valuation allowance.

Outlook and guidance

• Fiscal 2025 total revenue guidance: $21.7–$21.9 billion, reflecting a $250 million FX headwind and 4.0%–4.5% organic growth.

• Adjusted EPS guidance raised to $14.30–$14.60 (10% growth at midpoint), absorbing $0.15 incremental FX impact.

• Q2 organic revenue growth expected to accelerate sequentially, excluding a 150 bps licensing headwind.

• Adjusted effective tax rate for FY25 expected between 14% and 15.25%; Q2 tax rate ~16.8%.

• More details on the planned separation to be provided by end of FY25.